AbbVie sees hope in hepatitis C, cancer drugs in development
This article was originally published in Scrip
Executive Summary
AbbVie financial chief Bill Chase told investors that the company is in good position to capture a piece of the market for hepatitis C treatments and touted the company’s experimental cancer therapies in development.